Margaret Dohnalek

INC Research (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Milo D. Hilty

Nationwide Children's Hospital

Edward Balish

Medical University of South Carolina

J Farmer

Lahey Medical Center

R. Doug Wagner

United States Food and Drug Administration

T. Warner

John Hunter Hospital

L Roberts

University of Wisconsin–Madison

C Pierson

University of Wisconsin–Madison

Wagner Rd

University of Wisconsin–Madison

M. Lourdes Guerrero

UConn Health

Guillermo M. Ruíz-Palacios

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Cooperative Institutions

University of Wisconsin–Madison

Chungbuk National University

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Ewha Womans University

Novarex (South Korea)

Kyungpook National University

Suntory (Japan)

Cornell University

Ross Laboratories (United States)

Highland Community College - Illinois

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Spirulina

International Journal of Noncommunicable Diseases (2021)

Subbu Kesavaraja Vasudevan Suresh Seetharam Margaret Dohnalek Elizabeth J. Cartwright

In recent years, the various health benefits of Cyanobacteria microalgae – such as Arthrospira platensis , commonly called Spirulina, an edible blue-green algae – have attracted scientific attention including micro-level examinations of its bioactive components. As a whole food and nutritional supplement, it serves as a plant protein source, which has shown positive effects across a wide range of human health concerns, from malnutrition to metabolic syndrome. Spirulina bioactives, such as essential amino acids, phycocyanin, polysaccharides, carotenoids, and chlorophyll, and essential vitamins and trace minerals, are responsible for its holistic actions against oxidative stress and inflammation, and its antiviral, antibacterial, and immune-modulating effects. Various in vitro, in vivo , and ex vivo experiments have established Spirulina's mechanism of action and its effect on immunity as a proof of concept. The phenolic compounds and extracellular metabolites released from Spirulina whole food after digestion are postulated to strengthen the epithelial lining with antibacterial effects against pathogenic bacteria, adding to its prebiotic effect on the gut microbiota (like Bifidobacterium and Lactobacillus) due to its fiber content. In this study, the digestibility of Spirulina was assessed by the determination of free amino acids and peptide release during the each phase of digestion in a simulated static digestive model system. The hypothesis bridging poor gut health to low-level inflammation and metabolic syndrome, and the potential to address those issues with nutritional supplementation, such as with Spirulina, could also be beneficial in the long run to reduce comorbid illnesses, such as those associated with the currently prevailing coronavirus disease 2019 pandemic.

Spirulina (dietary supplement)

Functional food

Fucoidan

Prebiotic

Digestion

10.4103/2468-8827.330650

Cite

Citations (4)

Subchronic (13-week) oral toxicity study, preceded by an in utero exposure phase, with arachidonate-enriched triglyceride oil (SUNTGA40S) in rats

Food and Chemical Toxicology (2005)

B.A.R. Lina André Wolterbeek Yoshihiro Suwa Shigeaki Fujikawa Yoshiyuki Ishikura

10.1016/j.fct.2005.08.002

Cite

Citations (32)

TOLERANCE AND FECAL COLONIZATION WITH Lactobacillus reuteri IN CHILDREN FED A BEVERAGE WITH A MIXTURE OF Lactobacillus spp.1090

Pediatric Research (1996)

Guillermo M. Ruíz-Palacios Fernando Tuz Fernando Arteaga M. Lourdes Guerrero Margaret Dohnalek

Lactobacillus reuteri

10.1203/00006450-199604001-01112

Cite

Citations (16)

FlexPro MD®, a Combination of Krill Oil, Astaxanthin and Hyaluronic Acid, Reduces Pain Behavior and Inhibits Inflammatory Response in Monosodium Iodoacetate-Induced Osteoarthritis in Rats

Nutrients (2020)

Minhee Park Jae Chul Jung Stephen J. Hill Elizabeth J. Cartwright Margaret Dohnalek

Osteoarthritis (OA) is a degenerative joint disease and a leading cause of adult disability. Since there is no cure for OA and no effective treatment to slow its progression, current pharmacologic treatments, such as analgesics and non-steroidal anti-inflammatory drugs (NSAIDs), only alleviate symptoms, such as pain and inflammation, but do not inhibit the disease process. Moreover, chronic intake of these drugs may result in severe adverse effects. For these reasons, patients have turned to the use of various complementary and alternative approaches, including diverse dietary supplements and nutraceuticals, in an effort to improve symptoms and manage or slow disease progression. The present study was conducted to evaluate the anti-osteoarthritic effects of FlexPro MD® (a mixture of krill oil, astaxanthin, and hyaluronic acid; FP-MD) in a rat model of OA induced by monosodium iodoacetate (MIA). FP-MD significantly ameliorated joint pain and decreased the severity of articular cartilage destruction in rats that received oral supplementation for 7 days prior to MIA administration and for 21 days thereafter. Furthermore, FP-MD treatment significantly reduced serum levels of the articular cartilage degeneration biomarkers cartilage oligomeric matrix protein (COMP) and crosslinked C-telopeptide of type II collagen (CTX-II), and the pro-inflammatory cytokines tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), as well as mRNA expression levels of inflammatory mediators, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), and matrix-degrading enzymes, matrix metalloproteinase (MMP)-2 and MMP-9, in the knee joint tissue. Our findings suggest that FP-MD is a promising dietary supplement for reducing pain, minimizing cartilage damage, and improving functional status in OA, without the disadvantages of previous dietary supplements and medicinal agents, including multiple adverse effects.

Type II collagen

10.3390/nu12040956

Cite

Citations (28)

Effects of probiotic bacteria on humoral immunity to Candida albicans in immunodeficient bg/bg-nu/nu and bg/bg-nu/+ mice.

PubMed (2000)

R. Doug Wagner Margaret Dohnalek Milo D. Hilty Andrés Vázquez‐Torres Edward Balish

Lactobacillus casei

Source

Cite

Citations (15)

FEEDING OF A PROBIOTIC FOR THE PREVENTION OF COMMUNITY-ACQUIRED DIARRHEA IN YOUNG MEXICAN CHILDREN. † 1089

Pediatric Research (1996)

Guillermo M. Ruíz-Palacios M. Lourdes Guerrero Milo D. Hilty Margaret Dohnalek Pamela Newton

10.1203/00006450-199604001-01111

Cite

Citations (16)

Efficacy and Safety of a Joint Health Nutritional Supplement for Subjects with Non-arthritic Knee Joint Pain: A Double-blind, Placebo- and Active-Controlled, Randomized Clinical Trial

Journal of Orthopedic Research and Therapy (2023)

Margaret Dohnalek Elizabeth J. Cartwright Wendy Hill

We evaluated the efficacy and safety of FlexPro MD ® (FP-MD), a combination of krill oil, astaxanthin, and hyaluronic acid, in adults with non-arthritic knee joint pain.This multicenter, double-blind, placebo-and active-controlled study randomized 140 adults 1:1:1 to oral glucosamine hydrochloride/chondroitin sulfate (GC), FP-MD, or placebo once daily for 8 weeks.Mean percentage decreases in clinician-rated WOMAC pain scores were 35% (FP-MD), 21 % (GC), and 20% (placebo) at week 2, and 55% (FP-MD), 35% (GC), and 30% (placebo) at week 8. Overall, the mean percentage decrease in pain was significantly greater (P<0.0001) for FP-MD than for either GC or placebo subjects.FP-MD subjects experienced significantly greater reductions in WOMAC pain scores compared with GC (P=0.004) and placebo (P=0.011) at week 8 (post-hoc pairwise comparisons).Reductions in patient-reported VAS pain scores followed a similar pattern.FP-MD was three times more effective than GC for pain reduction (63% of FP-MD vs. 16% of GC subjects pain free at week 8).Incidence of adverse events was low (7 [14.9%]GC subjects; 5 (10.2%)FP-MD subjects), with headache being most commonly reported.Once-daily FP-MD supplementation significantly reduced joint pain, measured by both clinicians and subjects, compared with both GC and placebo, and was well tolerated.

Joint pain

10.29011/2575-8241.001272

Cite

Citations (1)

Variable biotherapeutic effects of Lactobacillus acidophilus isolates on orogastric and systemic candidiasis in immunodeficient mice.

PubMed (1998)

Wagner Rd T. Warner L Roberts J Farmer Margaret Dohnalek

Systemic candidiasis

Source

Cite

Citations (17)

Biotherapeutic effects of probiotic bacteria on candidiasis in immunodeficient mice

Infection and Immunity (1997)

R. Doug Wagner C Pierson T. Warner Margaret Dohnalek J Farmer

Four species of probiotic bacteria were assessed for their capacities to protect athymic bg/bg-nu/nu and euthymic bg/bg-nu/+ mice from mucosal and systemic candidiasis. Each bacterial species and Candida albicans colonized the gastrointestinal tracts of both strains of mice. The presence of probiotic bacteria (Lactobacillus acidophilus, Lactobacillus reuteri, Lactobacillus casei GG, or Bifidobacterium animalis) in the gastrointestinal tracts prolonged the survival of adult and neonatal bg/bg-nu/nu mice compared to that of isogenic mice colonized with C. albicans alone. The incidence of systemic candidiasis in bg/bg-nu/nu mice was significantly reduced by each of the four probiotic bacterial species. The numbers of C. albicans present in the alimentary tracts of euthymic bg/bg-nu/+ mice were significantly reduced by L. casei GG and B. animalis. None of the probiotic bacteria species completely prevented mucosal candidiasis, but B. animalis reduced its incidence and severity. Probiotic bacteria also modulated antibody- and cell-mediated immune responses to C. albicans. The prolonged survival of mice, decreased severity of mucosal and systemic candidiasis, modulation of immune responses, decreased number of C. albicans in the alimentary tract, and reduced numbers of orogastric infections demonstrated not only that probiotic bacteria have biotherapeutic potential for prophylaxis against and therapy of this fungal disease but also that probiotic bacteria protect mice from candidiasis by a variety of immunologic (thymic and extrathymic) and nonimmunologic mechanisms in this model.

Lactobacillus casei

Bifidobacterium animalis

Systemic candidiasis

10.1128/iai.65.10.4165-4172.1997

Cite

Citations (181)

Probiotic Effects of Feeding Heat-Killed Lactobacillus acidophilus and Lactobacillus casei to Candida albicans-Colonized Immunodeficient Mice

Journal of Food Protection (2000)

R. Doug Wagner C Pierson Thomas F. Warner Margaret Dohnalek Milo D. Hilty

Lactobacillus casei

Systemic candidiasis

10.4315/0362-028x-63.5.638

Cite

Citations (98)